Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRemacemide hydrochloride
Description: NMDA antagonist; blocks ion channel and allosteric modulatory site
Alternative Names: FPL 12924AA
Chemical Name: 2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for Remacemide hydrochloride
Remacemide hydrochloride is an non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50 = 8 - 68 mM). Remacemide hydrochloride is anticonvulsant in vivo and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na+ channels (IC50 = 161 mM). In an animal model of Huntington's disease, extends survival and delays disease; this effect is more pronounced when combined with Coenzyme Q10 (Cat. No. 3003)
Licensing Information
Sold with the permission of AstraZeneca UK Ltd.
Technical Data for Remacemide hydrochloride
| M. Wt | 304.82 |
| Formula | C17H20N2O.HCl |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 111686-79-4 |
| PubChem ID | 60510 |
| InChI Key | HYQMIUSWZXGTCC-UHFFFAOYSA-N |
| Smiles | Cl.CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Remacemide hydrochloride
References for Remacemide hydrochloride
References are publications that support the biological activity of the product.
Palmer et al (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann.N.Y.Acad.Sci. 765 236 PMID: 7486610
Santangeli et al (2002) Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur.J.Pharmacol. 438 63 PMID: 11906711
Subramaniam et al (1996) Block of the N-MthD.-aspartate receptor by remacemide and its des-glycine metabolite. J.Pharmacol.Exp.Ther. 276 161 PMID: 8558426
Ferrante et al (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J.Neurosci. 22 1592 PMID: 11880489
View Related Products by Target
View Related Products by Product Action
Keywords: Remacemide hydrochloride, Remacemide hydrochloride supplier, NMDA, antagonists, blocks, ion, channel, allosteric, modulatory, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, AstraZeneca, FPL, 12924AA, 1622, Tocris Bioscience
Citations for Remacemide hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Remacemide hydrochloride.
Reviews for Remacemide hydrochloride
There are currently no reviews for this product. Be the first to review Remacemide hydrochloride and earn rewards!
Have you used Remacemide hydrochloride?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.